---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-009664"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2024-02-02T23:59:59+00:00"
generated_at: "2026-06-06T09:46:03.305911+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Cellectar reports share count update after warrant exercises; 30.45M common shares outstanding as of Jan 31, 2024

## Summary
- Common shares outstanding: 30,452,042 as of January 31, 2024, up from prior count due to Tranche A and other warrant exercises since November 2023.
- Preferred stock outstanding: 319.76 Series E-2, 918.00 Series E-3, and 111 Series D preferred shares.
- Warrant exercises increased share count, diluting existing common stockholders.
- No business updates or financial results provided; filing solely updates capital structure.

## SEC filing metadata
- accession: 0001104659-24-009664
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2024-02-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465924009664/0001104659-24-009664-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465924009664/tm244672d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-009664
- JSON: https://secwatch.observer/filing/0001104659-24-009664.json
- Plain text: https://secwatch.observer/filing/0001104659-24-009664.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.